科伦博泰生物-B(06990)于2025年欧洲肿瘤内科学会大会上公布的多项创新药物研究成果
SKB BIOSKB BIO(HK:06990) 智通财经网·2025-10-20 00:21

Core Viewpoint - The company announced the presentation of multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference held in Berlin from October 17 to 21 [1] Group 1: Clinical Research Results - The company presented data on the targeted antibody-drug conjugate (ADC) sac-TMT (佳泰莱®), which targets trophoblast cell surface antigen 2 (TROP2) [1] - The company also showcased results for the HER2-targeted ADC A166 (舒泰莱®) [1] - Additionally, data related to the Claudin18.2 (CLDN18.2) ADC SKB315 was presented [1]